Payment overview · 2025
General Payments
$55.07
3 reported records · 3 companies
Healthcare provider profile · identity verified
Karah Freeman Smith, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · DALTON, GA · NPI 1285622746
Verified facts
What the public records show
CMS Open Payments records show Karah Freeman Smith, PA-C received $55.07 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.01 | 36.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.80 | 32.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.26 | 31.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.07 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 351 | 101 |
| Lisinopril | Lisinopril | 308 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 66 |
| Omeprazole | Omeprazole | 233 | 65 |
| Losartan Potassium | Losartan Potassium | 206 | 62 |
| Gabapentin | Gabapentin | 196 | 54 |
| Simvastatin | Simvastatin | 190 | 58 |
| Meloxicam | Meloxicam | 188 | 52 |
| Trazodone Hcl | Trazodone Hcl | 184 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 49 |
| Clonazepam | Clonazepam | 169 | 50 |
| Metformin Hcl | Metformin Hcl | 165 | 50 |
| Potassium Chloride | Potassium Chloride | 157 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 154 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 35 |
| Sertraline Hcl | Sertraline Hcl | 117 | 34 |
| Furosemide | Furosemide | 114 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 22 |
| Jardiance | Empagliflozin | 96 | 16 |
| Tramadol Hcl | Tramadol Hcl | 88 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 31 |
| Alendronate Sodium | Alendronate Sodium | 79 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 24 |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Estradiol | Estradiol | 67 | 23 |
| Carvedilol | Carvedilol | 65 | 17 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 19 |
| Ozempic | Semaglutide | 62 | 13 |
| Famotidine | Famotidine | 60 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 19 |
| Allopurinol | Allopurinol | 56 | 15 |
| Lorazepam | Lorazepam | 56 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 16 |
| Mirtazapine | Mirtazapine | 49 | 16 |
| Prednisone | Prednisone | 49 | 43 |
| Cephalexin | Cephalexin | 44 | 35 |
| Cefuroxime | Cefuroxime Axetil | 43 | 41 |
| Eliquis | Apixaban | 43 | 11 |
| Ramipril | Ramipril | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 25 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 19 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 27 |
| Naproxen | Naproxen | 29 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 22 |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.07 · 3 records | Abbott Laboratories | FREESTYLE LIBRE 3, INCEPTIV, Korlym | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error